Characterization of the galU Gene of Streptococcus pneumoniae Encoding a Uridine Diphosphoglucose Pyrophosphorylase: A Gene Essential for Capsular Polysaccharide Biosynthesis

By Marta Mollerach,* Rubens López,‡ and Ernesto García‡

From the *D departamento de Microbiología, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires 1113 Buenos Aires, Argentina; and the ‡Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas, 28006 Madrid, Spain

Summary

The galU gene of Streptococcus pneumoniae has been cloned and sequenced. Escherichia coli cells harboring the recombinant plasmid pMMG2 (galU) overproduced a protein that has been shown to correspond to a uridine 5′-triphosphate:glucose-1-phosphate uridylyltransferase (uridine diphosphoglucose [UDP-Glc] pyrophosphorylase) responsible for the synthesis of UDP-Glc, a key compound in the biosynthesis of polysaccharides. A gene very similar to the S. pneumoniae galU has been found in a partial nucleotide sequence of the Streptococcus pyogenes genome. Knockout galU mutants of type 1 pneumococci are unable to synthesize a detectable capsule. An identical result was found in type 3 S. pneumoniae cells in spite of the fact that these bacteria contain a type-specific gene (cap3C) that also encodes a UDP-Glc pyrophosphorylase.

Since eukaryotic UDP-Glc pyrophosphorylases appear to be completely unrelated to their prokaryotic counterparts, we postulate that GalU may be an appropriate target for the search of new drugs to control the pathogenicity of bacteria like pneumococcus and S. pyogenes.

Key words: pneumococcus • capsule • UDP-Glc pyrophosphorylase • virulence • galU

S treptococcus pneumoniae (pneumococcus) remains a major cause of morbidity and mortality throughout the world and its continuous increase in antimicrobial resistance is rapidly becoming a leading cause of concern for public health. Pneumococcal infection persists as the main causative agent of pneumonia, meningitis, and otitis media. These diseases remain as the most prevalent infections in many areas of the world, particularly in infants, the elderly, and in immunocompromised patients. As shown in a recent study (1), although a 68% reduction in total invasive diseases due to H influenzae type b was observed in the United States after licensure of the conjugated vaccine, a concomitant increase of 74% in the number of cases per 100,000 population for invasive pneumococcal diseases was also found. Although S. pneumoniae produces several virulence factors (for review see reference 2), as early as 1928 Griffith reported that unencapsulated pneumococcal variants were avirulent (3), and that loss of the capsule is accompanied by a 105-fold reduction of the virulence of S. pneumoniae. Uncapsulated pneumococci are readily phagocytized when added to a suspension of leukocytes in normal serum, whereas mucoid, capsulated organisms are resistant to phagocytosis and multiply rapidly. A quantitative relationship between the amount of type-specific polysaccharide and virulence has been found (4, 5), although the chemical composition of the capsule (6) as well as the cellular background in which the capsule is produced also appear to play an important role in virulence (7).

90 different pneumococcal types have been described (8). This remarkable phenotypic variability appears to be present also at the genetic level (9–11), which has precluded until now the search for drugs capable of inhibiting the synthesis of the capsular polysaccharides of S. pneumoniae. The chemical structure of the repeat unit of these polysaccharides is known in more than half of the types described, most of them contain glucose (Glc)1 and/or galactose (Gal) or various derivatives of them in addition to other sugars (12). Early studies carried out by Mills and co-workers (for review see reference 13) showed that uridine diphosphoglucose (UDP-Glc) is a key component in

1 Abbreviations used in this paper: Gal, galactose; GAS, group A streptococci; Glc, glucose; Ln, lincomycin; UDP-GalA, uridine diphosphogalacturonic acid; UDP-Glc, uridine diphosphoglucose; UDP-GlcA, uridine diphosphoglucuronic acid; UDPG:PP, uridine diphosphoglucose pyrophosphorylase.
the biosynthetic pathway of pneumococcal capsular polysaccharides containing Glc, Gal, and/or UDP-glucuronic (UDP-GlcA) or UDP-galacturonic (UDP-GalA) acids (Fig. 1). The enzyme UTP:glucose-1-phosphate uridylyltransferase (UDP-Glc pyrophosphorylase, UDPG:PP) (EC 2.7.7.9) catalyzes the formation of UDP-Glc, which is the substrate for the synthesis of UDP-GlcA. UDP-Glc is also required for the interconversion of Gal and Glc by way of the Leloir pathway (14), and consequently, mutants of Escherichia coli deficient in UDPG:PP activity cannot ferment Gal and fail to incorporate Glc and Gal into bacterial cell membranes, resulting in the incomplete synthesis of lipopolysaccharide (15). The gene cap3C of S. pneumoniae, one of the three genes located in the type 3–specific capsular operon, encodes a UDPG:PP that has been shown to be dispensable for capsule production (16, 17). This result strongly suggests that another different gene might also encode a UDPG:PP that, in addition, might be common to all of the pneumococci. In favor of this assumption is the fact that, apart from cap3C, a gene putatively encoding a UDPG:PP has not been found in any of the capsular clusters studied so far (9–11).

A partial (and still preliminary) nucleotide sequence of the genome of a type 4 pneumococcus has been released recently (ftp://ftp.tigr.org/pub/data/s_pneumoniae). This has allowed the search for genes coding for proteins similar to the Cap3C pyrophosphorylase and we report here the cloning, expression, and characterization of the galU gene of S. pneumoniae. We show that the pneumococcal galU mutants of types 1 and 3 did not synthesize detectable amounts of capsular polysaccharide.

Materials and Methods

Bacterial Strains, Plasmids, and Growth Conditions. The bacterial strains and the plasmids used in this study are shown in Table 1. Unless otherwise stated, S. pneumoniae was grown in liquid C medium (18) containing 0.08% yeast extract (C + Y) without shaking or on reconstituted tryptose blood agar base plates (Difco Laboratories Inc., Detroit, MI) supplemented with 5% defibrillated sheep blood. E. coli cells were grown in Luria-Bertani medium (19). When required, ampicillin was added to the medium at 100 μg/ml. Chromosomal DNA and plasmid purification, and transformation of E. coli and laboratory strains of S. pneumoniae were carried out as described elsewhere (20). S. pneumoniae clones obtained upon transformation with pUC19 or pMG1 (Table 1) were scored on blood agar plates containing 0.7 μg of lincomycin (Lm) per ml. MacConkey agar plates (Difco Laboratories, Inc.) containing 0.6% galactose were used for E. coli fermentation tests.

DNA Techniques and Plasmid Construction. Restriction endonucleases, T4 DNA ligase, and the Klenow (large) fragment of DNA polymerase I were obtained commercially and used according to the recommendations of the suppliers. Gel electrophoresis of plasmids, restriction fragments, and PCR products was carried out in agarose gels as described (19). DNA was recovered from gel slices with the Gene Clean Kit (Bio 101, La Jolla, CA).

S. pneumoniae DNA digested with either SmaI, SalI, or Apal was analyzed by pulsed-field gel electrophoresis (PFGE) using a contour-clamped homogeneous electric field DRII apparatus (Bio-Rad, Hercules, CA) as previously described (21).

PCR amplifications were performed using 2 U of AmpliTaqTM DNA polymerase (Perkin-Elmer Applied Biosystems, Norwalk, CT), 1 μg of chromosomal (or plasmid) DNA, 1 μM of each synthetic oligonucleotide primer, 200 μM of each deoxynucleoside triphosphate, and 2.5 mM of MgCl2 in the buffer recommended by the manufacturer. Conditions for amplification were chosen according to the G + C content of the corresponding oligonucleotide. The oligonucleotides used were: (624), 5′-TTGTTACCTGAAA-CACCTGGCATGC-3′ (primer OGalU1); (1139/c) 5′-CCAA-CGTCGAATACGAGC-3′ (primer OGalU2); (1464/c), 5′-GAGCAGTATGGGGCGATTTAGC-3′ (primer OGalU3); (323), 5′-TGATGAGGCTTTACCCTCTATAGGAAG-3′ (primer OGalU4); (659/c), 5′-GAAATGAAGGCCGATGCCAGGTG-3′ (primer IGalU1); (773), 5′-CGAGAAGGCCTTCTCTCTGAC-3′ (primer IGalU2). Numbers indicate the position of the first nucleotide of the primer in the sequence reported in this paper (see below), and /c means that the corresponding sequence corresponds to the complementary strand. Lowercase letters indicate nucleotides introduced to construct appropriate restriction sites. These are shown underlined. For inverse PCR, DNA prepared from strain 406 was digested with ClaI, and the resulting fragments were diluted 10-fold and self-ligated. Afterwards, the DNA was concentrated by ethanol precipitation and amplified by PCR using oligonucleotides IGalU1 and IGalU2.

To construct pMMG2 (Table 1), DNA prepared from the type 3 strain 406 was amplified with oligonucleotides OGalU3 and OGalU4 and the 1.1-kb DNA fragment was purified, digested with MluI and SalI, and ligated to EcoRI/Sall-digested pUC19. Plasmid pMMG1, which contains a 0.5-kb internal fragment of the gene galU (Table 1), was constructed as follows: DNA prepared from strain 406 was amplified with primers OGalU1 and OGalU2 and the 0.5-kb DNA fragment was purified, digested with KpnI and ClaI, and ligated to pUC191 previously digested with KpnI plus Accl.

NEBiolot™ Phototopel™ Kit was used to construct biotin-labeled probes and Phototopel™ 6K Detection Kit was used for the chemiluminescent detection. Southern blots, dot blots, and hybridizations were carried out according to the manufacturer’s instructions.

![Figure 1. Metabolic pathway of UDP-Glc.](image-url)
Nucleotide Sequence and Data Analysis. DNA sequencing was carried out by using an Abi Prism 377™ DNA sequencer (Applied Biosystems Inc., Foster City, CA). DNA and protein sequences were analyzed with the Genetics Computer Group software package (version 9.0) (22). Sequence similarity searches were done by using the EMBL/GenBank, SWISS-PROT, and PIR databases.

SDS-PAGE and NH₂-terminal Amino Acid Sequence Analysis. SDS-PAGE was carried out as described by Laemmli using 10% gels (23). After SDS-PAGE, proteins were blotted onto a polyvinylidene difluoride membrane (Immobilon-P™, Millipore Corp.), and stained briefly with Amido black (Sigma Chemical Co., St. Louis, M.O.). Subsequently, the desired band was cut and the NH₂-terminal amino acid sequence was determined as described elsewhere (24).

Miscellaneous Techniques. The test for carbohydrate fermentation by pneumococcal strains was carried out in Heart infusion broth (Difco Laboratories, Inc.) with the appropriate carbohydrate added at 1% (final concentration) as previously described (25). For immunoagglutination assays (26), S. pneumoniae cells were incubated on C medium containing 0.1% BSA and different amounts of anti-R antiserum. Anti-R (antisomatic) antiserum contains group-specific agglutinins that, at a convenient dilution, agglutinate only rough pneumococci, and was raised in rabbits as

| Strain or plasmid | Relevant genotype or phenotype | Source or reference |
|-------------------|-------------------------------|---------------------|
| **S. pneumoniae** |                               |                     |
| 13868             | S1⁺ LytA⁺                     | 20                  |
| 9060              | S1⁺ LytA⁺                     | 20                  |
| 14388             | S1⁺ LytA⁺                     | 20                  |
| M 25              | S1⁺ lytA                      | 20                  |
| M 25g*            | galU::pUCE191 lytA            | T his study         |
| 406               | S3⁺ LytA⁺                     | 45                  |
| M 23              | S3⁺ lytA                      | 45                  |
| M 23c†            | cap3C::pUCE191 lytA           | 16                  |
| M 23g‡            | galU::pUCE191 lytA            | T his study         |
| M 24              | cap3A (S₃⁻) lytA              | 45                  |
| M 24g§            | galU::pUCE191 lytA            | T his study         |
| 335/95            | S5⁺ LytA⁺                     | A. Fenoll           |
| 6028/95           | S8⁺ LytA⁺                     | A. Fenoll           |
| 536/96            | S9⁺ LytA⁺                     | A. Fenoll           |
| 13783/90          | S14⁺ LytA⁺                    | A. Fenoll           |
| 17A               | S17A⁺ LytA⁺                   | Statens Seruminstitut |
| 8249              | S19A⁺ LytA⁺                   | 46                  |
| 436/96            | S31⁺ LytA⁺                    | A. Fenoll           |
| SSISP 33A/1       | S33A⁺ LytA⁺                   | Statens Seruminstitut |
| 1235/89           | S37⁺ LytA⁺                    | A. Fenoll           |

**E. coli strains**

| Strain or plasmid | Relevant genotype or phenotype | Source or reference |
|-------------------|-------------------------------|---------------------|
| D H 5x            | (φ80IaZΔM15) endA 1 recA 1 hsdR 17 (rK⁻ mK⁻) supE 44 ΔIadJ 169 thi-1 leuB thr-1 | 47                  |
| T G 1             | supE hsd Δ55 thi Δ(lac-proA B) F' (traD 36 proA B + Iad₉ lacZ ΔM15) | 19                  |
| FF4001            | M C 4100 galU 95              | 48                  |

**Plasmids**

| Strain or plasmid | Relevant genotype or phenotype | Source or reference |
|-------------------|-------------------------------|---------------------|
| pUC19             | C loning vector (Ap⁺)         | 49                  |
| pUCE191           | C loning vector (Ap⁺, Ln²)    | 16                  |
| pUCEK2            | Internal fragment of cap3C cloned into pUCE191 | 16                  |
| pM MG1            | 0.45-kb internal fragment of S. pneumoniae galU cloned into pUCE191 | T his study         |
| pM MG2            | galU gene from S. pneumoniae strain 406 cloned into pUC19 | T his study         |

*Strain constructed by transformation of M 25 with DNA from strain M 24,g.
†Strain constructed by transformation of M 23 with pUCEK2.
‡Strain constructed by transformation of M 23 with DNA from M 24,g.
§Strain constructed by transformation of M 24 with pMEG1.
Results

Identification, Cloning, Sequencing, and Mapping of a Pneumococcal Gene Similar to cap3C. The deduced amino acid sequence of the cap3C gene was compared to the translated version of the nucleotide sequence of a type 4 pneumococcal strain that has been released recently. A gene (hereafter designated galU) encoding a protein 77% identical to Cap3C was located in the 12,128-bp contig No. 4225. Analysis of this gene and its surrounding regions (Fig. 2) revealed that contig No. 4225 does not contain the type 4-specific capsular cluster which appears to be localized in the contig No. 4108 (34,280 bp). The putative galU gene is preceded by a gene whose product showed strong similarity to the GpsA NAD(P)H-dependent dihydroxyacetone-phosphate reductase of Bacillus subtilis (28) (Table 2). The galU and the gpsA genes are only 21 bp apart. Other genes surrounding gpsA-galU were preliminarily identified on the basis of sequence similarities with the exception of orf5 and orf6, which did not show any significant similarities to those available in the data banks.

Preliminary efforts to amplify by PCR the galU gene using DNA prepared from the S. pneumoniae type 3 strain 406 were unsuccessful when using oligonucleotide primers designed from the nucleotide sequence of genes gpsA and orf5 from type 4 pneumococci. However, successful amplification was achieved with OGalU3 and OGalU4, which correspond to the 5' end of orf6 and to the 3' end of gpsA, respectively. The 1.1-kb PCR fragment was cloned into pUC19 to create pMMG2 (Table 1). Moreover, inverse PCR using oligonucleotides IGalU1 and IGalU2 (designed from the nucleotide sequence of the Sall-Munl insert of pMMG2) produced a 2.3-kb DNA fragment that was partially sequenced. Determination of the sequence of 1,464 bp revealed that the orf5 gene was not present in 406 DNA, which accounts for the amplification failures discussed above. It should be noted that the nucleotide sequence of the galU gene (900 bp) was nearly identical (89%) to that of the type 4 isolate (not shown).

The absence of orf5 in strain 406 prompted us to analyze whether other important differences exist among various pneumococcal isolates. Southern blot analysis of HindIII-digested chromosomal DNA prepared from a variety of pneumococcal strains using a 0.7-kb Sall-ClaI fragment of pMMG2 showed that all the strains tested contain at least one copy of the galU gene (Fig. 3). In the case of strains 6028/95 (S8+) and SSIP 33A/1 (S33A+), the pattern of hybridization might suggest the existence of a second copy of galU in their DNAs, although we favor the hypothesis that the 5.5-kb DNA band was incompletely cleaved in those two strains. Nevertheless, this point was not further investigated.

Fig. 4 shows a multiple alignment of the amino acid sequence of the galU gene product with the proteins available in the databases. HasC, a UDPG:PP from the has operon required for expression of the hyaluronic acid capsule of Streptococcus pyogenes (29), showed the highest similarity to the pneumococcal GalU (>85% identical amino acids and 90.9% similarity). About 87% sequence similarity (77% identity) was found between the pneumococcal GalU and Cap3C proteins. Although not yet included in the data banks, a search of a partial nucleotide sequence of the S. pyogenes genome (http://www.genome.ou.edu/strep.html) for genes similar to galU (and hasC) showed that, as in S. pneumoniae, group A streptococci (GAS) also contain a galU homologue located in the contig No. 234 (8061 bp) (Fig. 2). The similarity between the GalU proteins of S. pneumoniae and S. pyogenes was even higher than that found between the former and the type 3-specific Cap3C UDPG:PP of S. pneumoniae (Fig. 4). Lower but significant similarities were also found between the pneumococcal GalU and UDPG:PPs from B. subtilis (30) and E. coli (31) as well as with the GalF protein of E. coli that modulates the activity of the GalU enzyme (32).

To determine the location of galU in the pneumococcal genome, chromosomal DNA of strain M24, a descendant of the classical laboratory strain R6 (33), was digested with Smal, Apal, or SacII, subjected to PFGE, blotted, and hybridized with the 0.7-kb Sall-ClaI fragment of pMMG2 (see above). The results shown in Fig. 5 indicated that the galU gene resides in fragments S (SmaI, 235 kb), 4 (Apal, 235 kb), and 13 (SacII, 54 kb) of the physical map of the pneumococcal genome (34).

Overproduction and Characterization of the S. pneumoniae GalU Protein. E. coli DH5α cells harboring pMMG2 were incubated overnight at 37°C with shaking in LB me-
dium containing ampicillin (100 μg/ml). Crude extracts obtained by sonication were analyzed by 10% SDS-PAGE and a prominent protein band of ~37 kD was observed (Fig. 6, lane 2). This band was absent in crude extract prepared from E. coli DH5α cells containing the vector plasmid pUC19 (Fig. 6, lane 3). The molecular mass of the 37-kD overproduced protein was in fair agreement with that deduced from the nucleotide sequence of the galU gene (33,213 D). It should be mentioned that an apparent 38,000 Mr has been reported for the purified E. coli GalU whereas a molecular mass of 32,291 D was predicted from the sequence of the galU gene (31). The NH2-terminal amino acid sequence of the protein was determined, yielding Met-Thr-Ser-Lys-Val-Arg-Lys-Ala-Val-Ile, which confirmed the sequence deduced from the nucleotide sequence of the gene (Fig. 4).

To ascertain that the pneumococcal galU gene codes for a UDPG:PP, the pGM M2 plasmid was introduced by transformation into the galU E. coli mutant strain FF4001. This mutant contains a T to C mutation causing the substitution of a proline residue by a serine one in the predicted amino acid sequence of the GalU protein and virtually lacks UDPG:PP activity (31). Ampicillin-resistant transformants scored on MacConkey-galactose plates grew as red colonies indicating that they were able to ferment the sugar (not shown). This result confirmed that the galU gene of S. pneumoniae encodes a UDPG:PP.

Construction and Characterization of galU Mutants of Pneumococcus.
To construct galU mutants of S. pneumoniae lacking UDPG:PP, insertion-duplication mutagenesis was carried out using plasmid pMMG1 that contains an internal fragment of the galU gene cloned into pUCE191 (Table 1).
A Ln-resistant transformant (designated as M24g) was isolated upon transformation of the pneumococcal strain M24 with pMMG1 isolated from E. coli TG1. Carbohydrate-fermentation tests showed that M24g fermented Glc but was unable to use Gal as a carbon source (not shown).

Chromosomal DNA prepared from strain M24g was used to transform the encapsulated strains M23 (S31) and M25 (S11), and Ln-resistant clones were picked for further study. As found for M24g, the transformant strains M23g and M25g were also unable to ferment Gal whereas M23c did ferment either Glc or Gal. Furthermore, when the M23g strain was grown in blood agar plates, small, rough-like colonies were formed, in sharp contrast with the big, smooth colonies typical of type 3 strains of S. pneumoniae (Fig. 7). As reported before (16), no major differences were observed between the colonies of M23 and M23c strains. Since type 1 pneumococcal strains form small colonies, no significant differences were found on the morphology of the colonies of M25 and M25g (not shown). Encapsulated pneumococci grow typically in suspension when incubated in broth, whereas unencapsulated mutants show a tendency to aggregate at the bottom of the tube. The pneumococcal galU mutants, but not the cap3C mutants (M24c), grew as true unencapsulated strains (Fig. 7) and were agglutinated with anti-R serum (not shown). Moreover, immunodiffusion analysis of cell extracts using either type 1- or type 3-specific antisera demonstrated that M23g and M25g did not synthesize any detectable capsular polysaccharide (Fig. 7). In contrast, M23c produced type 3 polysaccharide in amounts comparable to the M23 strain, which confirmed previous results (16). To further confirm that GalU is essential for the biosynthesis of capsular polysaccharides in S. pneumoniae, strains M23g and M25g were repeatedly subcultured in Ln-free C medium containing 0.1% BSA and anti-R antiserum (see Materials and Methods). After several passages, putatively encapsulated revertants that were not agglutinated by the serum and thus grew in suspension were isolated. They appeared to be true galU+ revertants as judged from the findings that were no longer Ln-resistant and that the size (1.1 kb) of the PCR fragments obtained by using oligonucleotide primers OGalU3 and OGalU4...
and DNA isolated from every revertant tested corresponded to that of the intact galU gene (see above). As expected, those revertants were able to synthesize a capsular polysaccharide corresponding to the original, encapsulated parental strain (type 1 or type 3) as demonstrated immunologically (data not shown).

Discussion

Duplicated genes appear to be rather unusual in bacteria and consequently type 3 pneumococci and S. pyogenes are somehow exceptional in having two genes coding for the same enzyme, namely, a UDPG:PP. The capsular polysaccharides of both bacteria contain glucuronic acid, and the genes responsible for their biosynthesis are organized in a similar fashion (16, 35), i.e., each operon contains three genes, the gene responsible for the synthesis of UDP-Glc (cap3C and hasC, in S. pneumoniae and GAS, respectively), the gene encoding a UDP-Glc dehydrogenase (ap3A and hasA), and the gene coding for the enzyme responsible for the synthesis of the type 3 polysaccharide in S. pneumoniae (cap3B) or hyaluronic acid in S. pyogenes (hasA). As shown for type 3 pneumococci where cap3C is not required for capsule formation, only HasA and HasB appear to be required for hyaluronic acid capsule production both in GAS and in heterologous bacteria as revealed by Tn916 mutagenesis (36, 37). Furthermore, a gene very similar to the pneumococcal galU gene described here has been found in the partial nucleotide sequence of the S. pyogenes genome that is currently available. It should be mentioned that, both in S. pneumoniae and S. pyogenes, the galU is immediately preceded by a gene (gpsA) that is presumably involved in the synthesis of membrane lipids (28). The significance of this finding is not currently understood but it is interesting to point out that gpsA and galU genes are completely unlinked in other bacteria such as B. subtilis or E. coli.

Figure 6. Expression of the GalU protein of S. pneumoniae by E. coli containing the recombinant plasmid pMMG2. E. coli DH5α cells containing either pMMG2 or pUC19 vector alone were incubated overnight on LB medium, and the crude sonicated extracts were analyzed by 10% SDS-PAGE. Lane 2, extracts from bacteria containing pMMG2. Lane 3, extracts from bacteria harboring pUC19. The molecular masses of the standards (lane 1) are indicated on the left.

Figure 7. Unencapsulated phenotype of the pneumococcal galU mutants. (Top) Colony morphology on blood-agar plates. Bar, 1 mm. (Middle) Growth characteristics after overnight incubation at 37°C in C+Y medium. (Bottom) Double immunodiffusion in agarose. The center wells received type 3 (a) or type 1 (b) antisera. The pneumococcal strains analyzed were: M23 (A); M23 c (cap3C) (B); M23 g (GalU) (C); M25 (D); M25 g (GalU) (E). Purified pneumococcal polysaccharides from type 1 (1) and type 3 (3) were used as positive controls.

Figure 8. Domain arrangement of several UDPG:PP from prokaryotic and eukaryotic organisms. Bars represent domains and identical shading indicates high amino acid sequence similarity. The proteins were aligned according to programs available at the ProDom database (reference 50). The number assigned to each domain (#) as well as its length in amino acid residues (aa) are indicated at the top right. The UDPG:PP aligned correspond to the following species: E. coli (Eco GalU); B. subtilis (Bsu GtaB); S. pyogenes (Spy HasC and Spy GalU); S. pneumoniae (Spn Cap3C and Spn GalU); Bos Taurus (UDPG_Bovin); Homo sapiens (UDPG_Human); S. cerevisiae (UDPG_Yeast and UDPG_Yeast); Solanum tuberosum (UDPG_SolTu); and Dictyostelium discoideum (UDPG_DicDi).
A relevant role of UDP-G:PP for virulence has been recognized in various gram-negative bacteria (38–40). However, to the best of our knowledge, there are no data available in gram-positive organisms concerning the importance of this protein in pathogenicity. In this work, we have constructed galU mutants of two strains of *S. pneumoniae* of different serotypes, namely types 1 and 3. Both mutants were unencapsulated according to a series of criteria, i.e., colony morphology, growth in liquid medium, agglutinability with anti-R serum, and lack of recognition by type-specific antiserum. On the other hand, galU revertants of strains M 23 g and M 25 g synthesized type 1 and type 3 capsules, respectively. The unencapsulated phenotype of the galU mutants was expected in the case of the type 1 strain that apparently does not harbor any other gene encoding a UDPG:PP in addition to galU (20). However, in type 3 pneumococci the unencapsulated phenotype of the galU mutants was somehow surprising since these bacteria contain an active copy of cap3C that also codes for the same enzymatic activity (16). Since Cap3C UDPG:PP activity is not required for type 3 capsule formation and it cannot replace the activity lost in the galU mutants we conclude that, at least under laboratory conditions, either Cap3C is poorly translated or its enzymatic activity is very low. As the HaaC protein of *S. pyogenes* is also not needed for hyaluronate biosynthesis (see above), it can be predicted that galU mutants of GAS will be also unencapsulated. This observation might be of remarkable clinical relevance since loss of capsule is associated with a 100-fold reduction in virulence of *S. pyogenes* (41).

The continuous dissemination of multiply resistant *S. pneumoniae* clones throughout the world is the cause of great concern, and much effort is currently dedicated to the search for new antibacterial drugs (42, 43). The polysaccharide capsule of pneumococcus is the main virulence factor of this bacterium (3) and drugs inhibiting its biosynthesis should potentially render *S. pneumoniae* virtually avirulent. Unfortunately, the noticeable genetic variability found in the genes responsible for the capsular polysaccharide biosynthesis has precluded until now the search for such drugs. Remarkably, the galU gene has been found in all the pneumococcal types tested so far (Fig. 3). The UDPG:PP, which is directly involved in the synthesis of the capsular polysaccharide in *S. pneumoniae* and other bacterial pathogens, might represent a suitable target for the search of inhibitors of such an important virulence factor. In this sense, it should be emphasized that eukaryotic UDPG:PPs appear to be completely unrelated to their prokaryotic counterparts (for review see reference 44). As depicted in Fig. 8, the structural arrangement of the domains found in prokaryotic UDPG:PP is remarkably similar. In contrast, the eukaryotic enzymes exhibit a completely different arrangement as well as a different amino acid sequence. This interesting feature suggests the possibility that putative inhibitors of the bacterial enzymes would not be harmful for the host.

**References**

1. Schuchat, A., K. Robinson, J.D. Wengert, L.H. Harrison, M. Farley, A.L. Rengold, L. Lefkowitz, and B.A. Perkins. 1997. Bacterial meningitis in the United States in 1995. N. Engl. J. Med. 337:970–976.
2. Alonso-DeVealaco, E., A.F. Verheul, J. Verhoef, and H. Snippe. 1995. Streptococcus pneumoniae virulence factors, pathogenesis, and vaccines. Microbiology. Rev. 59:591–603.
3. Griffith, F. 1928. The significance of pneumococcal types. J. Hyg. 27:113–159.
4. MacLeod, C.M., and M.R. Krauss. 1950. Relation of virulence of pneumococcal strains for mice to the quantity of capsular polysaccharide formed in vitro. J. Exp. Med. 92:1–9.
5. MacLeod, C.M., and M.R. Krauss. 1953. Control by factors distinct from the S transforming principle of the amount of capsular polysaccharide produced by type III pneumococci. J. Exp. Med. 97:767–771.
6. Knecht, J.C., G. Schiffman, and R. Austrian. 1970. Some biological properties of pneumococcus type 37 and the chemistry of its capsular polysaccharide. J. Exp. Med. 132:475–487.
7. Kelly, T., J.P. Dillard, and J. Yother. 1994. Effect of genetic switching of capsular type on virulence of Streptococcus pneumoniae. Infect. Immun. 62:1813–1819.
8. Henrichsen, J. 1995. Six newly recognized types of Streptococcus pneumoniae. J. Clin. Microbiol. 33:2759–2762.
9. García, E., and R. López. 1997. Molecular biology of the capsular genes of Streptococcus pneumoniae. FEMS (Fed. Eur.
13. Mills, G.T., and E.E.B. Smith. 1965. Biosynthesis of capsular subunit. M ol. M icrobiol. 26:197–208.
14. van Dam, J.E., A. Fleer, and H. Snippe. 1990. Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharides. A ntonie van L eeuwenhoek. 58:1–47.
15. Mills, G.T., and E.E.B. Smith. 1965. Biosynthesis of capsular subunit. M ol. M icrobiol. 26:197–208.
16. Arrecubieta, C., E. García, and R. López. 1995. Sequence analysis of proteins on PVDF membranes.
17. Frey, P.A. 1996. The Leloir pathway: a mechanistic imperative for three enzymes to change the stereochemical configuration of a single carbon in galactose.
18. Lacks, S., and R.D. Hotchkiss. 1960. A study of the genetic material determining an enzyme activity in Pneumococcus. B ioc hem. Biol. 7367.
19. Sambrook, J., E.F. Fritsch, and T. M aniatis. 1989. M olecular C loning. A Laboratory Manual. C old Spring Harbor Laboratory, C old Spring Harbor, N.Y. 6.22–6.31; A.12.
20. Muñoz, R., M. Mollerach, R. López, and E. García. 1997. M olecular organization of the genes required for the synthesis of type 1 capsular polysaccharide in Streptococcus pneumoniae: formation of binary encapsulated pneumococci and identification of cryptic dTDP-rhamnose biosynthesis genes. M ol. M icrobiol. 25:79–92.
21. Arrecubieta, C., R. López, and E. García. 1994. M olecular characterization of cap3A, a gene from the operon required for the synthesis of the capsule of Streptococcus pneumoniae type 3: sequencing of mutations responsible for the unencapsulated phenotype and localization of the capsular cluster on the pneumococcal chromosome. J. B acteriol. 176:6375–6383.
22. Deverieux, J., P. H eberli, and O. S mithies. 1984. A comprehensive set of sequence analysis programs for the VAX. N ucleic Acids R es. 12:387–395.
23. Lauterbach, J.K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. N ature. 227: 680–685.
24. Speicher, D.W. 1994. Methods and strategies for the sequence analysis of proteins on PVDF membranes. M ethods. 6:262–273.
25. R uoff, K.L. 1995. Streptococcus, In M anual of C linical M icrobiology, 6th ed. P.R. M urray, E.J. B aron, M.A. P fiffer, F.C. T enover, and R.H. Y olken, editors. A merican Society for M icrobiology, W ashington, D.C. 299–307.
26. A rrecubieta, C., R. López, and E. García. 1996. Type 3–specific synthase of Streptococcus pneumoniae (Cap3B) directs type 3 polysaccharide biosynthesis in Escherichia coli and in pneumococcal strains of different serotypes. J. E xp. M ed. 184: 449–455.
27. M orbidoni, H.R., D. de Mendoza, and J.E. C ronan. 1995. Synthesis of sn-glycerol 3-phosphate, a key precursor of membrane lipids, in B aillus subtilis. J. B acteriol. 177:5909–5915.
28. Crater, D.L., B.A. Dougherty, and I. van de R ijn. 1995. M olecular characterization of hasc’ from an operon required for hyaluronic acid synthesis in group A streptococci. J. B iol. C hem. 270:28676–28680.
29. Soldo, B., V. Lazarevic, P. M argot, and D. Karamata. 1993. Sequencing and analysis of the divergon comprising galB, the structural gene of UDP-glucose pyrophosphorylase, in B aillus subtilis 168. J . G en. M icrobiol. 139:3185–3195.
30. W eisburn, A.C., Q. L iu, M.K. R umley, and E.P. K ennedy. 1994. UTP-α-d-glucose-1-phosphate uridylyltransferase of Escherichia coli: isolation and DNA sequence of the galU gene and purification of the enzyme. J. B acteriol. 176:2611–2618.
31. M arolda, C.L., and M. A va. 1996. The GalF protein of Escherichia coli is not a UDP-glucose pyrophosphorylase but interacts with the GalU protein possibly to regulate cellular levels of UDP-glucose. M ol. M icrobiol. 22:827–840.
32. A very, O.T., C.M. M acLeod, and M. M cCarty. 1944. Studies on the chemical nature of the substance inducing transformation of pneumococcal types. Induction of transformation by a deoxyribonucleic acid fraction isolated from pneumococcus type III. J. E xp. M ed. 79:137–158.
33. G aac, A.M., L. Kauc, P. B arrallé, M. Sicard, and S. G oodgal. 1991. Gene localization, size, and physical map of the chromosome of Streptococcus pneumoniae. J. B acteriol. 173:7561–7567.
34. A very, O.T., C.M. M acLeod, and M. M cCarty. 1944. Studies on the chemical nature of the substance inducing transformation of pneumococcal types. Induction of transformation by a deoxyribonucleic acid fraction isolated from pneumococcus type III. J. E xp. M ed. 79:137–158.
42. Tomasz, A. 1994. Multiple-antibiotic-resistant pathogenic bacteria. A Report on the Rockefeller University Workshop. N. Engl. J. Med. 330:1247–1251.

43. Lawler, A. 1995. Antibiotics that resist resistance. Science. 270:724–727.

44. Flores-Díaz, M., A. Alape-Girón, B. Persson, P. Pollesello, M. Moos, C. von Eichel-Streiber, M. Thelestam, and I. Florin. 1997. Cellular UDP-glucose deficiency caused by a single point mutation in the UDP-glucose pyrophosphorylase gene. J. Biol. Chem. 272:23784–23791.

45. García, E., P. García, and R. López. 1993. Cloning and sequencing of a gene involved in the synthesis of the capsular polysaccharide of Streptococcus pneumoniae type 3. Mol. Gen. Genet. 239:188–195.

46. Liu, H.H., and A. Tomasz. 1985. Penicillin tolerance in multiply drug-resistant natural isolates of Streptococcus pneumoniae. J. Infect. Dis. 152:365–372.

47. Hanahan, D. 1983. Studies on transformation of E. coli with plasmids. J. Mol. Biol. 166:557–580.

48. Giæver, H.M., O.B. Styrvold, I. Kaasen, and A.R. Strøm. 1988. Biochemical and genetic characterization of osmoregulatory trehalose synthesis in Escherichia coli. J. Bacteriol. 170:2841–2849.

49. Yanisch-Perron, C.J., J. Vieira, and J. Messing. 1985. Improved M13 phage cloning vectors and host strains: nucleotide sequence of M13mp18 and pUC19 vectors. Gene (Amst.). 33:103–119.

50. Corpet, F., J. Gonzy, and D. Kahn. 1998. The ProDom database of protein domain families. Nucleic Acids Res. 26:323–326.